Showing results (401-410 of 458) with videos related to

Sort By:
Pageof 46
British Journal of Cancer|September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update databaseJakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Future Oncology (London, England)|April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancerThomas Powles, Se Hoon Park, Eric Voog, et al.
The New England Journal of Medicine|August 23, 2013
Pazopanib versus sunitinib in metastatic renal-cell carcinomaRobert J Motzer, Thomas E Hutson, David Cella, et al.
The Journal of Urology|November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinomaRoberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
The Lancet. Oncology|June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Pageof 46